Clinical Trials Logo

Colchicine Resistance clinical trials

View clinical trials related to Colchicine Resistance.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05418686 Completed - Clinical trials for Colchicine Resistance

Study of Colchicine Resistance in Familial Mediterranean Fever

COLCHI-RESIST
Start date: December 9, 2022
Phase: N/A
Study type: Interventional

Five to 10% of familial mediterranean patients are considered colchicine-resistant (i.e. patients with a persistent inflammatory syndrome, despite taking the maximum tolerated dose of colchicine daily). The recommended treatment in this case is a subcutaneous anti-interleukin 1 biotherapy (anakinra or canakinumab). These treatments are expensive (1,000 to 12,000 euros/month). However, for a patient to be considered colchicine-resistant, compliance with the treatment must be verified. Furthermore specific activation of the pyrin inflammasome by Clostrioides difficile toxin and the overrepresentation of these bacteria in the stools of our patients led us to systematically search for them in our resistant patients. The demonstration of the involvement of C. difficile in the imbalance of the disease has not yet been published. The colchiresist study aim to better characterize colchicine-resistance by confirming good compliance to treatment with colchicine hair measurement and by looking for clostrioides infection or intestinal dysbiosis.